Pharmaceutical Intermediate Nootropic New Product Compound 7p CAS 1890208-58-8 CAS NO.1890208-58-8

Advantages:

Hubei XinRunde Chemical Co., Ltd is a renowned pharmaceutical manufacturer. We can offer high quality products at competitive price in quick delivery with 100% custom pass guaranteed. Never stop striving to offer our best service is our philosophy. We have Flexible and Untraceable payment terms. As a leading manufacture, our products have been exported to Germany, Norway, Poland, Finland, Spain, UK, France, Russia, USA, Brazil, Mexico, Australia, Japan, Korea, Thailand, Indonesia, Uruguay and many other countries.

1. Quality.Every batch of steroid powders have tobetested by our QC(quality control) before they are allowed to sell.

2. Delivery We have stock, so we can delivery quickly at the very day when receive the payment. Within 24 hours after receiving the payment Lead time 4 or 7 days.

3. Discreet package Safelyand Professionally Disguised Package Guaranteed. For your safety and to insure delivery all products will be packed in a discreet way to prevent any suspicions, no steroids related name will appear on the parcels. high successful delivery rate.

4. Warm after-sale service Any of your question would be solved for the first as soon as possible.

Pharmaceutical Intermediate Nootropic New Product Compound 7P  CAS 1890208-58-8

Introduction:

Chemical Name: 2-[(2-methoxyphenyl)[(4-methylphenyl)sulfonyl]amino]-N-(4-methoxy-3-pyridinyl)acetamide ;2-(N-(2-methoxyphenyl)-4-methylphenylsulfonamido)-N-(4-methoxypyridin-3-yl)acetamide

CAS No.: 1890208-58-8

Reaxys Registry Number: 29568294
Molecular Formula: C22H23N3O5S
Molecular Weight: 441.508

Assay:99%min
InChI Key: NAXWKPFXCOBXLE-UHFFFAOYSA-N

Density(Predicted): 1.329±0.06 g/cm3 |Condition:Temp:20 Press:760Torr

Function:

Axon regeneration after injury in the central nervous system is hampered in part because if an age-dependent decline in the intrinsic axon growth potential , and one of the strategies to stimulate axon growth in injured neurons involves pharmacological manipulation of implicated signaling pathways.here we report phenotypic cell-based screen of chemical libraries and structure-activity-guided optimization that resulted in the identification of compound 7p which promotes neurite outgrowth of cultured primary neurons derived from the hippocampus, cerebral cortex, and retina. in an animal model of optic nerve injury, compound 7p was shown to induce growth of gap-43 positive axons, indicating that the in vitro neurite outgrowth activity of compound 7p translates into stimulation of axon regeneration in vivo.further optimization of compound 7p and elucidation of the mechanisms by which it elicits axon regeneration in vivo will provide a rational basis for future efforts to enhance treatment strategies.

Application:

 Increases coordination

 Improves mood

 Helps fight fatigue

 Prevents oxidation within the brain

 Treats alcohol related brain damage

Compound 7p was developed as one in series of compounds with the aim of identifying dual-acting thromboxane receptor antagonist/synthase inhibitors . In fact compound 7p shows selectivity for prostaglandin I2 synthase (PTGIS , CYP8A1) over thromboxane synthase (CYP5A1) .

Axon regeneration after injury in the central nervous system is hampered in part because if an age-dependent decline in the intrinsic axon growth potential, and one of the strategies to stimulate axon growth in injured neurons involves pharmacological manipulation of implicated signaling pathways .

Here we report phenotypic cell-based screen of chemical libraries and structure-activity-guided optimization that resulted in the identification of compound 7p which promotes neurite outgrowth of cultured primary neurons derived from the hippocampus, cerebral cortex, and retina .

In an animal model of optic nerve injury, compound 7p was shown to induce growth of GAP-43 positive axons, indicating that the in vitro neurite outgrowth activity of compound 7p translates into stimulation of axon regeneration in vivo. Further optimization of compound 7p and elucidation of the mechanisms by which it elicits axon regeneration in vivo will provide a rational basis for future efforts to enhance treatment strategies .